BioSelective Capital Investments, through its acquisition of BioDuro’s Irvine-based drug product development and manufacturing operations, has launched Forma Life Sciences Inc., a newly created CDMO specializing in oral solid dosage forms. The transaction includes two legacy facilities with established U.S. Food and Drug Administration (FDA) regulatory histories—Fairbanks and Jeronimo—spanning over 100,000 square feet combined. Now operating under the Forma name, the facilities serve both clinical-stage and commercial-phase drug developers, offering scale-up flexibility and a bioavailability enhancement roadmap at a time when reshoring pressures and innovation demands are converging.
What this changes for oral solid dosage outsourcing in a saturated CDMO market
Forma’s emergence reflects a tactical bet on oral drug products amid a backdrop of intense competition and shifting capacity priorities across the CDMO industry. While injectables and biologics continue to dominate investor headlines, the oral solid dosage segment remains the volume anchor for global drug delivery, accounting for over 60% of all marketed pharmaceuticals.
In the U.S., the CDMO landscape for oral formulations has historically skewed toward large incumbents—such as Catalent, Thermo Fisher Scientific (through Patheon), and Recipharm—leaving mid-tier innovators with limited domestic options. Forma enters this vacuum with inherited GMP compliance, client continuity, and facilities capable of accommodating both early-stage scale-up and commercial batch production. Industry observers suggest this lowers the onboarding risk typically associated with newly formed CDMOs, potentially allowing Forma to compete for time-sensitive Phase III tech transfers and lifecycle management reformulations.
What this reveals about operational control models in private equity-backed CDMOs
Unlike conventional financial investors that rely on operational incumbents for execution, BioSelective Capital Investments deploys a hybrid model that embeds operational leadership into the acquisition thesis from day one. With Cyrus K. Mirsaidi assuming both Executive Chairman and Acting CEO roles, Forma is designed for aggressive post-acquisition alignment—a structure more akin to industrial roll-up models than traditional hands-off private equity.
This approach reflects a broader pattern in the CDMO sector: asset carve-outs are increasingly being reshaped by capital partners who not only deploy funding but directly drive sales acceleration, capacity utilization, and technological differentiation. In Forma’s case, the rapid transition from transaction close to operational relaunch suggests that BioSelective is seeking early revenue traction from both retained and new clients.
Investors tracking CDMO buyouts note that while many transactions falter in the integration phase due to IT disjointedness, employee attrition, or facility revalidation delays, BioSelective’s continuity-first approach and retained staff structure may mitigate those transition risks. However, this advantage must be weighed against the challenge of building a scalable business without the broader infrastructure support that former parent entities like BioDuro typically provide.
Why the focus on bioavailability and in silico modeling is more than a capability upgrade
Forma’s stated intent to expand into amorphous solid dispersion (ASD) and computational modeling-based formulation is not a routine capability checklist—it marks a deliberate attempt to position the company in the high-differentiation end of the oral dosage value chain. ASD technologies are increasingly critical for formulating poorly soluble new chemical entities (NCEs), a trend being amplified by advances in high-throughput screening and AI-led drug discovery that are generating more structurally complex molecules.
In silico formulation modeling—still nascent across many mid-size CDMOs—has become a key enabler for accelerating development timelines, reducing formulation trial cycles, and improving prediction of in vivo behavior. Forma’s stated ambition to build these tools in-house, rather than license third-party platforms, could enable it to offer value beyond manufacturing capacity: as a development partner capable of rational formulation design.
Clinicians familiar with drug development pipelines highlight that compounds targeting CNS, oncology, and metabolic disorders often suffer from erratic absorption and low oral bioavailability. CDMOs that can mitigate these through advanced formulation science, particularly within the 12–24 month clinical-to-commercial window, stand to gain disproportionate influence over developer outsourcing decisions.
How legacy infrastructure enables faster regulatory leverage—but comes with limitations
The legacy FDA inspection history of the Fairbanks and Jeronimo facilities is a central strength of the Forma launch narrative. In a sector where greenfield facilities can take 2–3 years to reach inspection readiness, acquiring validated assets offers a compressed timeline to GMP operations. For clinical-stage biopharma companies under accelerated regulatory designations, the ability to plug into a compliant manufacturing partner without process transfer delays can be a decisive factor.
However, legacy infrastructure also imposes ceilings. Without significant capital investment in equipment upgrades, automation, and digital quality management systems, older CDMO sites can fall behind newer facilities optimized for continuous manufacturing or adaptive batch processing. Forma will need to balance the advantages of immediate compliance with the demands of future-proofing its physical and digital infrastructure.
In parallel, the company’s ability to pivot into newer oral formats—such as abuse-deterrent formulations, multiparticulate systems, or modified-release capsules—will hinge on whether existing cleanroom layouts and process equipment can accommodate such versatility. This is particularly relevant as payers increasingly scrutinize delivery system enhancements as a basis for pricing differentiation.
What this means for global CDMO competitiveness and reshoring dynamics
Forma’s relaunch takes place against a larger backdrop of pharmaceutical supply chain localization. The COVID-19 pandemic, followed by geopolitical disruptions, has reignited U.S. interest in repatriating pharmaceutical manufacturing—especially for critical and high-volume dosage forms. While most federal incentives to date have focused on active pharmaceutical ingredients (APIs) and sterile injectables, the oral solid dosage segment is increasingly being recognized as a strategic category for domestic resilience.
If Forma can effectively position itself as a U.S.-based, tech-forward, cost-disciplined CDMO, it could benefit from this realignment. However, it remains to be seen whether domestic clients will pay a premium for local manufacturing in a pricing-sensitive generics market or whether global biotechs seeking U.S. entry points will favor a smaller partner without integrated drug substance capabilities.
Furthermore, as multinational CDMOs expand capacity in India, Singapore, and Europe to attract global clients with lower costs and higher automation, Forma must carve a clear differentiation strategy that goes beyond geography. This may include modular capacity, custom client service models, or integration with digital health platforms that track batch release and delivery in real time.
What clients and regulators are likely to monitor in Forma’s first year
For existing BioDuro clients transitioned to Forma, immediate concerns will likely center on business continuity: will batch timelines hold? Will quality systems remain stable? Will tech transfer documents remain traceable under the new entity? Regulatory watchers will expect Forma to demonstrate not just a paper-based transition but evidence of functional quality assurance integration, chain-of-custody controls, and robust supplier qualifications under new ownership.
Forma’s ability to win net-new clients may hinge on articulating a clear differentiator beyond standard oral CDMO claims. In a saturated market, showing success in complex formulations or rescue reformulations that failed elsewhere could create reputational lift. However, client acquisition may be constrained by limited therapeutic bandwidth or capacity utilization ceilings unless expansion plans are financed early.
Ultimately, Forma’s success will depend on whether it can execute at the intersection of operational speed, scientific precision, and regulatory fidelity—all while building a distinctive brand identity in a crowded field. BioSelective’s ability to transition from asset manager to integrated growth steward will be closely watched by others contemplating similar CDMO spinouts.
BioSelective Capital’s CDMO acquisition reshapes domestic pharma manufacturing landscape added by Pallavi Madhiraju on
View all posts by Pallavi Madhiraju →